Rituximab Effective, Durable in Refractory Myasthenia Gravis Rituximab Effective, Durable in Refractory Myasthenia Gravis

Dr Laurie Barclay discusses results from a small study and what they may mean for incorporating rituximab in the treatment of myasthenia gravis.Medscape Neurology
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Viewpoint Source Type: news

Related Links:

Publication date: Available online 23 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Molly Bates, Jason Chisholm, Eric Miller, Jagannadha Avasarala, Zain Guduru
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Contributors : Paola Cavalcante ; Carlo AntozziSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensPurpose: to identify specific miRNAs as biomarkers associated with immunosuppressive treatment response in MG patients.Methods: Blood miRNome profiles of 15 responder and 15 non-responder MG patients by miRNA-seq using Illumina NextSeq 500 sequencing. Raw data were de-multiplexed and FASTQ files for each sample were generated using the bcl2fastq software. FASTQ data were checked using the FastQC tool. After mapping the data and counting to relevant entries in miRBase 20 (http://www.mirba...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research
AbstractThe idea that B  cells participate in immune regulation was initially postulated from observations in animals in the 1970s. It is now established that certain B‐cell populations, known as regulatory B cells, regulate immune reactions in various animal models of autoimmunity, chiefly through the production of in terleukin‐10. Subsequent to these findings in animals, several B‐cell subsets have been identified in human blood that are capable of producing interleukin‐10 when stimulatedex vivo. Although we still do not have direct evidence showing that these interleukin ‐10‐producing B cells ...
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Tags: REVIEW ARTICLE Source Type: research
Source: eMedicineHealth.com - Category: General Medicine Source Type: news
No abstract available
Source: Neurology Today - Category: Neurology Tags: For Your Patients Source Type: research
Publication date: Available online 19 May 2020Source: Journal of Pediatric Surgery Case ReportsAuthor(s): Florence Ngu, Michael Cardamone, Dylan Wanaguru, Bruce Currie, Eva Alina Wegner, Ian Andrews, Walter Haindl
Source: Journal of Pediatric Surgery Case Reports - Category: Surgery Source Type: research
Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies predominantly against the acetylcholine receptor (AChR). Specific T cell subsets are required for long-term antibody responses, and cytokines secreted mainly from CD4+ T cells regulate B cell antibody production. The aim of this study was to assess the differences in the cytokine expressions of CD4+ T cells in MG patients with AChR antibodies (AChR-MG) and the effect of immunosuppressive (IS) therapy on cytokine activity and to test these findings also in MG patients without detectable antibodies (SN-MG). Clinically diagnosed AChR-MG and SN-MG patie...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
We read with interest the manuscript by Derderian et al. [1], and we support their enthusiasm for thymectomy for myasthenia gravis (MG), particularly with respect to minimally invasive techniques. However, we write to register our disappointment with their use of Osserman staging and deFilippi treatment classification, both of which are qualitative in nature and should not be mainstays of contemporary MG literature.
Source: Journal of Pediatric Surgery - Category: Surgery Authors: Source Type: research
Migliore L Abstract BACKGROUND: Hypermethylation of the growth hormone secretagogue receptor gene (GHSR) is increasingly observed in human cancers, suggesting that it could represent a pan-cancer biomarker of clinical interest. However, little is still known concerning GHSR methylation levels in thymic epithelial tumors, and particularly in thymomas from patients with Myasthenia Gravis (TAMG). MATERIAL AND METHODS: In the present study we collected DNA samples from circulating lymphocytes and surgically resected tumor tissues of 65 TAMG patients, and from the adjacent healthy thymic tissue available from 43 ...
Source: Gene - Category: Genetics & Stem Cells Authors: Tags: Gene Source Type: research
Source: International Journal of Neuroscience - Category: Neuroscience Authors: Source Type: research
More News: Brain | Myasthenia Gravis | Neurology | Neurosurgery | Rituxan | Study